Insilico Medicine
Generative AI drug discovery platform — from target identification to Phase 3 clinical trials with Pharma.AI
Gallery
4 items
About Insilico Medicine
Insilico Medicine is the world's leading generative AI-driven drug discovery and development company, responsible for advancing the first fully AI-discovered and AI-designed drug into human clinical trials. Founded in 2014 at Johns Hopkins University by Alex Zhavoronkov, Insilico is listed on the Hong Kong Stock Exchange (HKEX: 3696) and operates globally with R&D centers in the US, Greater China, Canada, and the Middle East — including a fully automated robotic laboratory in Suzhou connected directly to its Pharma.AI platform.
Pharma.AI, Insilico's proprietary end-to-end platform, covers the full drug discovery pipeline through three integrated modules: PandaOmics (AI-powered target identification and disease hypothesis generation from multi-omics and clinical data), Chemistry42 (generative AI for de novo molecule design), and InClinico (clinical trial outcome prediction). The platform has powered a pipeline of 31+ drug programs across 29 targets, with its lead drug rentosertib — a TNIK inhibitor for idiopathic pulmonary fibrosis — completing successful Phase 2a trials published in Nature Medicine and entering Phase 3 enrollment in 2026, making it the most advanced fully AI-designed drug in clinical history.
Insilico is the right partner for major pharmaceutical companies seeking to de-risk and accelerate early drug discovery through licensing collaborations (Sanofi, Fosun Pharma, Exelixis), and for biotechs and researchers exploring the frontier of generative AI in medicine. With revenue growing from $4.5M to $85M between 2021 and 2024 and $123M raised in its latest Series E, Insilico is the benchmark company in end-to-end generative AI drug discovery.
Key Features
- Pharma.AI end-to-end platform: PandaOmics (target ID), Chemistry42 (molecule design), InClinico (clinical prediction)
- Rentosertib (ISM001-055) — world's most advanced fully AI-discovered drug in Phase 3 for IPF
- 31+ drug programs across 29 targets in cancer, fibrosis, CNS, immunity, and aging
- Generative AI for de novo molecule design against novel and known drug targets
- Automated robotic laboratory in Suzhou connected directly to the AI platform
- 300+ patents filed, 200+ peer-reviewed publications in top scientific journals
- Multi-billion dollar licensing partnerships with Sanofi, Fosun Pharma, and Exelixis
- Chemistry42 generative AI designs novel molecules not found in existing chemical libraries
- PandaOmics AI for target identification using multi-omics, literature, and clinical data
- Listed on Hong Kong Stock Exchange (HKEX: 3696) — founded 2014 at Johns Hopkins University
Pros
- World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
- End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
- 300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
- Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
- Automated robotic lab in Suzhou closing the loop between AI design and physical testing
- Global presence: US, China, Canada, Middle East — with partnerships across big pharma
- Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing
Cons
- Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
- Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
- Dual-track model (platform + internal pipeline) adds operational complexity
- Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
- Listed on HKEX (Hong Kong) — less accessible to US institutional investors
Pricing
Insilico Medicine operates through two revenue streams: platform licensing and internal drug pipeline development.
Platform access: Pharmaceutical and biotech companies license the Pharma.AI platform (PandaOmics, Chemistry42, InClinico) through enterprise agreements for target identification, molecule design, and clinical prediction. Revenue is structured as upfront platform fees, milestone payments tied to drug program progress, and royalties on commercialized drugs.
Pipeline partnerships: Insilico licenses its AI-discovered drug candidates to pharma companies (e.g., Sanofi, Exelixis) for multi-million/billion dollar deals with upfront + milestone structures. Total revenue grew from $4.5M (2021) to $85M (2024). Contact Insilico through insilico.com for licensing and partnership inquiries.
Claim Verified Creator Badge
Are you the founder of Insilico Medicine? Display this listing's verified badge on your website to show your customers that your product has been vetted and listed on AI Central Resources.
<a href="https://www.aicentralresources.com/tool/insilico-medicine" target="_blank" rel="noopener"> <img src="https://www.aicentralresources.com/badges/featured-badge-dark.svg" alt="Featured on AICentralResources" width="200" height="54" style="border: none;" /> </a>
* Place this HTML snippet in your website's footer, landing page, or press section. This creates a search-friendly backlink directly to your verification page.
Connect with Insilico Medicine
Frequently Asked Questions
Insilico Medicine has the most advanced fully AI-generated drug pipeline in the world. Its lead drug, rentosertib (ISM001-055), was discovered and designed entirely by AI for idiopathic pulmonary fibrosis — it completed Phase 2a trials with positive results and entered Phase 3 in 2026. This makes Insilico the global leader in end-to-end generative AI drug discovery.
Pharma.AI is Insilico's end-to-end AI platform for drug discovery and development. It consists of three modules: PandaOmics (target identification and disease hypothesis generation), Chemistry42 (generative AI molecule design), and InClinico (clinical trial outcome prediction). Together they cover the full drug discovery pipeline from target to clinical prediction.
Rentosertib (ISM001-055) is Insilico's lead drug candidate — a TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) discovered and designed entirely by AI. Phase 2a results published in Nature Medicine showed a +98.4 mL improvement in FVC vs. a -20.3 mL decline on placebo. Phase 3 enrollment began in 2026, making it one of the most advanced AI-designed drugs in clinical history.
Insilico's revenue grew from $4.5M in 2021 to $85M in 2024, driven by landmark pharma licensing deals with Sanofi, Fosun Pharma, and Exelixis. The company raised $123M in its Series E round in 2025 and is listed on the Hong Kong Stock Exchange (HKEX: 3696).
Insilico Medicine has partnered with Sanofi (multi-target collaboration), Fosun Pharma, Exelixis (oncology), and numerous other pharma and biotech companies. It also licenses its Pharma.AI platform to organizations seeking to accelerate their own drug discovery pipelines.
Similar AI Tools to Insilico Medicine
View all alternatives of Insilico Medicine
Atomwise
Deep learning for structure-based drug discovery — AtomNet screens 16B+ compounds to find hits for any disease target
BenevolentAI
Clinical-stage AI drug discovery with integrated wet labs and AstraZeneca and Merck collaborations
Recursion Pharmaceuticals
AI-native drug discovery OS with industrial-scale automated labs and $500M+ in pharma partnerships
Schrödinger
Physics-based drug discovery with Bunsen AI co-scientist — trusted by 500+ pharma companies worldwide
Infermedica
AI clinical triage and symptom assessment platform — MDR Class IIb certified, 94% accuracy, 23M+ health checks
Tempus AI
AI precision medicine platform — genomic profiling, clinical insights, and trial matching for personalized cancer care
Compared with Insilico Medicine
Direct head-to-head feature matrices, pricing, and category breakdowns